Europe — EMA

Palonosetron Stada

Palonosetron, the active ingredient in Palonosetron Stada, is a 5‑HT3 receptor antagonist presented as a unknown/unknown for intravenous use.

Palonosetron

Request sourcing

Pack/s

What is Palonosetron?

Palonosetron, the active ingredient in Palonosetron Stada, is a 5‑HT3 receptor antagonist presented as a unknown/unknown for intravenous use. It treats and prevents chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Palonosetron Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

What is Palonosetron used for?

Palonosetron is a selective 5‑HT3 receptor antagonist used in the prevention of nausea and vomiting associated with chemotherapy. - Chemotherapy‑induced nausea and vomiting (CINV): Reduces the on‑c‑ … - Post‑post ... - - … - …

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →